To develop and commercialize novel, first-in-class therapeutics that meaningfully improve the lives of patients with kidney and vascular diseases.
To become a recognized leader in healthcare innovation and a trusted partner to the kidney and vascular communities.
Seek regulatory approval for vonapanitase and commercialize directly in the United States
Partner vonipanitase outside of the United States
Continue development of vonapanitase for additional indications
Build a pipeline of novel therapeutics in kidney and vascular diseases
Timothy Noyes is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. He has served as President, Chief Executive Officer and member of the board of directors at Proteon since 2006. Prior joining Proteon, he was the Chief Operating Officer of Trine Pharmaceuticals from 2002 to 2006 and held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. After the acquisition, from 2001 to 2002, he held the positions of President, Renal Division and President, GelTex Pharmaceuticals. Earlier in his career, Tim also spent several years at Merck, serving in multiple roles in its hypertension and heart failure group and managed care division. Tim received his A.B. from Harvard College and an M.B.A. from Harvard Business School.
Dr. Steven Burke has extensive drug development experience in both kidney and vascular disease and has been the Senior Vice President and Chief Medical Officer at Proteon since 2006. Before joining Proteon, he worked as Senior Vice President of Medical and Regulatory Affairs and Vice President of Clinical Research at Genzyme for six years. Steven has also held several positions at GelTex Pharmaceuticals, including Vice President of clinical research and medical director at Glaxo. He received an A.B. from Harvard College and an M.D. from
Cornell University Medical College. His medical residency and fellowship were completed at Brigham and Women’s Hospital and he is certified by the American Board of Internal Medicine.
George Eldridge’s financial background and expertise spans multiple industries, including biotechnology and investment banking. At Proteon, George has served as chief financial officer since 2013. From 2009 to 2013, he served as a consultant to companies in the biotech industry, acting as a Chief Financial Officer and providing advisory services. Prior to that, he held the roles of Chief Financial Officer at Targanta Therapeutics, Therion Biologics, Curis (previously Ontogeny) and Boston Life Sciences. George has also worked as an investment banker at Kidder Peabody. He holds a B.A. from Dartmouth College and an M.B.A. from the University of Chicago.
Pamela Gustafson joined Proteon in 2006 as the Director of Clinical Research, advanced to Senior Director of Clinical Research in 2012 and became the Vice President of Clinical Research in 2015. She brings a plethora of managerial skills to the leadership team, with over 25 years of experience in the clinical research field. Before joining Proteon, Pamela served as Director of Clinical Operations at Trine Pharmaceuticals. In addition, she has held several managerial positions at AAI International, LeukoSite, PAREXEL International and Alkermes. Pamela earned a B.A. from Wheaton College and an M.P.H. from Boston University. She is also certified as a Project Management Professional.